October 21, 2017 12:37 AM ET

Biotechnology

Company Overview of Samsung Bioepis Co., Ltd.

Company Overview

Samsung Bioepis Co., Ltd. develops and produces biopharmaceutical and biosimilar products. Samsung Bioepis Co., Ltd. has a strategic collaboration agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2012 and is based in Incheon, South Korea. Samsung Bioepis Co., Ltd. operates as a subsidiary of Samsung Biologics Co., Ltd.

107,Cheomdan-daero

Yeonsu-gu

Incheon,  406-840

South Korea

Founded in 2012

Phone:

82 3 2455 6114

Key Executives for Samsung Bioepis Co., Ltd.

Chief Executive Officer
Compensation as of Fiscal Year 2017.

Samsung Bioepis Co., Ltd. Key Developments

Samsung Bioepis Co., Ltd. Receives Positive CHMP Opinion on a Trastuzumab Biosimilar with ONTRUZANT®

Samsung Bioepis Co., Ltd. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on ONTRUZANT®, a biosimilar candidate referencing Herceptin® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. The CHMP’s positive opinion will now be referred to the European Commission (EC) which will decide on the grant of a marketing authorization for ONTRUZANT®. If a marketing authorization is granted by the EC, ONTRUZANT® will be commercialized in the European Union by MSD, which is known as Merck in the United States and Canada.

Samsung Bioepis First to Obtain European Commission Approval for a Third Anti-TNF-a Biosimilar with Imraldi® (Adalimumab)

Samsung Bioepis Co., Ltd. announced the European Commission’s (EC) approval of Imraldi®, a biosimilar referencing Humira® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis and uveitis.

Samsung Bioepis Co., Ltd. and Takeda Pharmaceutical Company Limited Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies

Samsung Bioepis Co., Ltd. announced that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. The risk-sharing partnership brings together Samsung Bioepis’ agile biologics development platform with Takeda’s experts in drug development to co-fund and collaboratively develop innovative therapies representing meaningful value to patients who need them. Additional terms of the collaboration are not being disclosed.

Similar Private Companies By Industry

Company Name Region
3billion, Inc. Asia
Abxign, Inc. Asia
AdipoGen, Inc. Asia
Advanced Protein Technologies Corporation Asia
Aetna Genetech Inc. Asia

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 10, 2017
--
Private Placement
November 22, 2016
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Samsung Bioepis Co., Ltd., please visit www.samsungbioepis.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.